2022 World Conference on Lung Cancer (ePosters)-EP08.01-048. Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT): Preliminary Analysis of the Lung Cancer Cohort

EP08.01-048. Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT): Preliminary Analysis of the Lung Cancer Cohort

Back to course

Pdf Summary

The Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT) is a national registry developed by several scientific societies and research institutions in Spain. The objective of this registry is to identify cardiovascular toxicity events in patients with solid tumors, particularly lung cancer, who are treated with immunotherapy for the first time. The registry includes 19 Spanish centers and aims to enroll 500 patients.<br /><br />Immunotherapy has revolutionized the treatment of lung cancer, but it also carries the risk of immune-related adverse events (irAEs), including cardiovascular complications. The registry aims to investigate the incidence and symptoms of cardiovascular irAEs and improve their management. It also seeks to validate a new biomarker for myocarditis and define the inflammation profile of these patients.<br /><br />Preliminary analysis of the lung cancer cohort in the registry shows that most participants are male, with a median age of 65 years. Many patients have a history of smoking and various cardiovascular risk factors such as hypertension, diabetes, and dyslipidemia. Some patients also have a history of cardiovascular diseases like myocardial infarction, heart failure, and cardiomyopathy.<br /><br />The results of this real-world registry will provide valuable insights into the incidence and management of cardiovascular irAEs. It will also aid in the development of monitoring protocols, identification of specific biomarkers, and prevention of adverse events. The authors suggest conducting a baseline cardiovascular study before initiating immunotherapy to detect any pre-existing cardiovascular conditions.<br /><br />Preliminary baseline characteristics of the lung cancer cohort, such as age, sex, histology, disease stage, type of immunotherapy, and cardiovascular parameters, are summarized in table 1. The median left ventricular ejection fraction, troponin levels, and NT-pro-BNP levels were also reported.<br /><br />The SIR-CVT registry is an important initiative that will contribute to improving the safety and outcomes of immunotherapy in cancer patients by better understanding and managing cardiovascular toxicity events.

Asset Subtitle

Laura Gutiérrez Sainz

Meta Tag

Speaker Laura Gutiérrez Sainz

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

SIR-CVT

lung cancer

immunotherapy

cardiovascular toxicity events

irAEs

biomarker

myocarditis

inflammation profile

baseline characteristics

safety of immunotherapy